Conflicts
of interest: The authors declare that they do not have any conflicts of interest. Authors’ contributions: All authors participated in the critical discussion of the results, and read and approved the final draft of the manuscript before submission. J. B.-F. prepared the data set and carried out the majority of data analysis and the writing of the manuscript. C. K. was responsible for database management, quality control, cleaning of data and data analysis. A. K. was responsible for data acquisition, quality control and co-ordination of the study. D. M.-K. was responsible for study co-ordination and data analyses in the early years of the study after implementation and contributed to the analysis. B. G.-B. supported the management and co-ordination of the study and contributed to improving data quality and coverage. O. H. was responsible Selleck PLX4032 for study design and the implementation of the project and supported the overall approach of the analyses and the writing of the manuscript. “
“Many HIV-infected patients with chronic hepatitis C virus (HCV) infection do not receive treatment for HCV infection, often because of contraindications or poor adherence
to anti-HIV therapy. The aim of this study was to identify factors influencing guideline-based HCV treatment initiation in a large cohort of HIV/HCV-coinfected patients. Between Z-VAD-FMK datasheet 2005 and 2011, 194 (40.5%) of 479 coinfected patients not previously treated for HCV infection started this treatment based on current recommendations, i.e. a Metavir score > F1 for liver fibrosis; HCV genotype 2 or 3 infection; or HCV genotype 1 or 4 infection and low HCV viral load (< 800 000 IU/mL), whatever the fibrosis score. Clinical and biological data were compared between patients who started HCV therapy during follow-up and those who did not. In multivariate
analyses, good adherence to treatment for HIV infection, as judged by the patient’s physician, was associated with HCV treatment initiation [odds ratio (OR) 2.37; 95% confidence interval (CI) 1.17–4.81; P = 0.017], whereas patients with children (OR 0.53; 95% CI 0.30–0.91; P = 0.022) and those with cardiovascular disease or respiratory distress (OR 0.10; 95% CI 0.01–0.78; P = 0.03) were Paclitaxel mw less likely to be treated. Adherence to treatment for HIV infection, as judged by the patient’s physician, appears to have a major influence on the decision to begin treatment for HCV infection in coinfected patients. This calls for specific therapeutic education and adherence support in order to ensure timely anti-HCV therapy in this population. “
“HIV-associated neurocognitive disorder (HAND) is an independent predictor of early mortality and is associated with many difficulties in activities of daily living. We sought to determine the prevalence of and risk factors for HAND in HIV-infected Koreans.